Stockwinners Market Radar for November 24, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:14 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The Medicines Company (MDCO) announced that it has entered into definitive agreement in which Novartis (NVS) will acquire the company for $85 per share in an all-cash transaction, implying a fully diluted equity value of $9.7B. The transaction was unanimously approved by the boards of both companies, and is expected to be completed in Q1 of 2020. 2. LVMH (LVMUY) is nearing a deal to acquire Tiffany & Co. (TIF) for over $16B, according to Bloomberg, citing people familiar with the matter. The updated proposal is for $135 per share, or 12% higher than the original $120 per share bid, the sources said, adding that a deal could be announced as soon as Monday. 3. HP Inc. (HPQ) sent a letter to Xerox (XRX) in response to Xerox's November 21 letter reiterating that HPO rejects Xerox's proposal which it believes significantly undervalues HP. The letter added that the proposal was "highly conditional and uncertain. In particular, there continues to be uncertainty regarding Xerox's ability to raise the cash portion of the proposed consideration and concerns regarding the prudence of the resulting outsized debt burden on the value of the combined company's stock even if the financing were obtained." Hp added that it was "not dependent on a Xerox combination." 4. Disney's "Frozen II" outperformed box office estimates, earning an around $127M domestically and $350M globally for the weekend, which was a record animated opening weekend in November -- as well as the fifth largest November opening weekend of all time. 5. Pfizer (PFE) and Charles Schwab (SCHW) saw positive mentions in this week's edition of Barron's, while VMware (VMW) and electric vehicles saw negative mentions.

18:16 EST EPR Properties sells charter school portfolio for $454M - EPR Properties announced that on November 22, it sold substantially all of its charter school portfolio, consisting of 47 charter school related assets, for approximately $454M of gross cash consideration to a fund sponsored by Rosemawr Management, LLC. This sale does not include three charter schools that the company sold previously in Q4 for proceeds of $21.6M and the one remaining charter school which the company expects to sell during Q4. The company also announced today that the sale of the charter school portfolio activates its strategic migration toward focusing its growth on experiential real estate. The company will also discontinue the organization of its portfolio around the discrete segments of Entertainment, Recreation and Education. Going forward the company's experiential portfolio will be organized by the primary property types targeted for growth in experiential real estate. These property types include: Theatres, Eat & Play, Ski, Attractions, Experiential Lodging, Gaming, Fitness & Wellness, Cultural and Live Venues. The company intends to rapidly redeploy the proceeds from the sale to fund investments in experiential real estate, including potential casino resort investments. Separately, the company has no present plans to sell its private school and early childhood education assets that are included in the Education portfolio, but will consider strategic dispositions if those opportunities present themselves in the future.

17:38 EST HP Inc. reiterates rejection of Xerox offer - HP Inc. (HPQ) announced that it sent a letter to Xerox (XRX) in response to Xerox's November 21 letter. "The HP Board of Directors has reviewed and considered your November 21 letter, which has provided no new information beyond your November 5 letter. We reiterate that we reject Xerox's proposal as it significantly undervalues HP. Additionally, it is highly conditional and uncertain. In particular, there continues to be uncertainty regarding Xerox's ability to raise the cash portion of the proposed consideration and concerns regarding the prudence of the resulting outsized debt burden on the value of the combined company's stock even if the financing were obtained. Consequently, your proposal does not constitute a basis for due diligence or negotiation. We believe it is important to emphasize that we are not dependent on a Xerox combination. We have great confidence in our strategy and the numerous opportunities available to HP to drive sustainable long-term value, including the deployment of our strong balance sheet for increased share repurchases of our significantly undervalued stock and for value-creating M&A. It is clear in your aggressive words and actions that Xerox is intent on forcing a potential combination on opportunistic terms and without providing adequate information. When we were in private discussions with you in August and September, we repeatedly raised our questions; you failed to address them and instead walked away, choosing to pursue a hostile approach rather than continue down a more productive path. But these fundamental issues have not gone away, and your now-public urgency to accelerate toward a deal, still without addressing these questions, only heightens our concern about your business and prospects. Accordingly, we must have due diligence to determine whether a Xerox combination has any merit. We remain prepared to study the potential value of a combination and to work quickly to learn more about your business trajectory. However, there are significant concerns about both the near-term health and long-term viability of your business that have a significant impact on Xerox's value. The question of whether there is a path to turn around your business is a threshold issue... The HP Board of Directors is committed to serving the best interests of HP shareholders, not Xerox and its shareholders. HP has numerous opportunities to create value for HP shareholders on a standalone basis. We will not let aggressive tactics or hostile gestures distract us from our responsibility to pursue the most value-creating path."

16:44 EST Partner Communications receives lawsuit - Partner Communications Company announced that the company received a lawsuit and a motion for the recognition of this lawsuit as a class action, filed against it and against two additional cellular operators in the Tel-Aviv District Court on November 17. In the motion it was allegedly claimed that the company, as well as the other respondents collected money from its customers for content services for third parties, by using the means of payment that were given to the company for the purpose of the cellular invoice payment, without receiving consent from these customers prior to the charge, and/or without having documentation with respect to the customers' consent, unlawfully and against its license provisions. The total amount claimed from each of the respondents if the lawsuit is recognized as a class action is NIS 400M in addition to compensation in the amount of NIS 500 for each one of the group members for non-monetary damages which were allegedly caused to them. An application for approval of a claim as a class action, filed solely against the company on October 7, 2010, for the same services, regarding the same period, was rejected by the District Court for the most part in 2016. An appeal that was filed to the Supreme Court by the applicants for that application against this judgment was dismissed in November 2018. The company is reviewing and assessing the lawsuit and is unable at this preliminary stage to evaluate, with any degree of certainty, the probability of success of the lawsuit or the range of potential exposure, if any.

15:25 EST The Medicines Co. acquired by Novartis for $85 per share in cash or $9.7B - The Medicines Company (MDCO) announced that it has entered into definitive agreement in which Novartis (NVS) will acquire the company for $85 per share in an all-cash transaction, implying a fully diluted equity value of $9.7B. The stock closed Friday down $1.21 to $68.55. The purchase price represents a premium of approximately 45% to The Medicines Company's closing share price of $58.65 on November 18, the last trading day prior to news reports of a potential transaction between The Medicines Company and Novartis. The transaction was unanimously approved by the boards of both companies. Under the terms of the merger agreement, Novartis will commence a tender offer to purchase all outstanding shares of The Medicines Company for $85 per share in cash. Following the completion of the tender offer, a wholly owned subsidiary of Novartis will merge with The Medicines Company and shares of The Medicines Company that have not been tendered and purchased in the tender offer will be converted into the right to receive the same price per share. Completion of the transaction is expected in Q1 of 2020, pending the successful completion of the tender offer and other customary closing conditions. Until that time, The Medicines Company will continue to operate as a separate and independent company. The company expects to file regulatory submissions for inclisiran in the U.S. in Q4 of 2019 and in Europe in the first quarter of 2020.